AAPL 184.35 1.1134% MSFT 411.6876 2.364% GOOG 145.3444 1.0459% GOOGL 144.175 1.14% AMZN 174.33 3.4047% NVDA 784.65 16.2927% META 486.18 3.878% TSLA 197.565 1.435% TSM 129.25 3.1195% LLY 769.655 3.1834% V 283.785 2.5383% AVGO 1304.8 6.3017% JPM 183.325 1.3405% UNH 525.425 0.6619% NVO 124.57 3.01% WMT 175.35 0.9499% LVMUY 182.36 1.7066% XOM 104.775 -0.0715% LVMHF 909.7617 1.9427% MA 471.85 2.7884%

blue-chip

Book Profit on this NASDAQ-Listed Bio-Technology Stock: Gilead Sciences Inc.

Aug 22, 2022 | Team Kalkine
Book Profit on this NASDAQ-Listed Bio-Technology Stock: Gilead Sciences Inc.

Gilead Sciences Inc.

Company Overview:  Gilead Sciences, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of medicine to prevent and treat diseases, including human immunodeficiency virus (HIV), viral hepatitis, and cancer.

As per the previous report published on GILD dated 29th April 2022, a ‘Buy’ stance was provided on the stock at USD 59.34 based on correction in the stock price, strong financial results, solid top-line performance, positive outlook, associated risks, technical analysis, and valuation and the stock price has now moved by ~ 10.11% since then and has now moved above resistance 1 and close to resistance 2.

Noted below are the details of support and resistance levels provided in the previous report:

GILD’s Daily Chart

Considering the resistance 1&2, current trading levels, risks associated, and volatile market conditions on the back of rising interest rates, a ‘Sell’ rating is assigned to the “GILD” at the closing market price of USD 65.34, as of August 19, 2022.  

Note: This report may be updated with details around fundamental and technical analysis, price/ chart in due course, as appropriate 

Note 1: Past performance is not a reliable indicator of future performance.

Note 2: The reference date for all price data, currency, technical indicators, support, and resistance levels is 29 April 2022. The reference data in this report has been partly sourced from REFINITIV.

Note 3: Investment decisions should be made depending on an individual's appetite for upside potential, risks, holding duration, and any previous holdings. An 'Exit' from the stock can be considered if the Target Price mentioned as per the Valuation and or the technical levels provided has been achieved and is subject to the factors discussed above.

Note 4: Target Price refers to a price level which the stock is expected to reach as per the relative valuation method and or technical analysis taking into consideration both short-term and long-term scenarios.

Note 5: ‘Kalkine reports are prepared based on the stock prices captured either from the New York Stock Exchange (NYSE), NASDAQ Capital Markets (NASDAQ), and or REFINITIV. Typically, all sources (NYSE, NASDAQ, or REFINITIV) may reflect stock prices with a delay which could be a lag of 15-20 minutes. There can be no assurance that future results or events will be consistent with the information provided in the report. The information is subject to change without any prior notice.’